Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ord Shs (OP: TKPHF )

27.64 +0.44 (+1.62%)
Streaming Delayed Price Updated: 9:30 AM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,205
Open 27.64
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 27.20
Today's Range 27.64 - 27.64
52wk Range 23.80 - 30.34
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Current Analysis: Takeda Pharmaceutical
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. Over the past year, Takeda’s share price fell 20.5% from $34.04 to $27.05 as of... 
Via Talk Markets
Current Analysis: Takeda Pharmaceuticals (TKPHF)
TKPHF is the largest Japanese drug company. Furthermore the estimated $45.50 dividend income from $1k invested is about 1.64 times greater than Friday’s price of a single share 
Via Talk Markets

Performance

YTD
-6.89%
-6.89%
1 Month
+2.37%
+2.37%
3 Month
-2.89%
-2.89%
6 Month
+6.46%
+6.46%
1 Year
-0.51%
-0.51%

More News

Read More
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
Via Benzinga
Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues
Via Benzinga
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
Via Benzinga
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
Via Benzinga
Takeda's Dengue Vaccine Candidate Under FDA Priority Review
Via Benzinga
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
Via Benzinga
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
Via Benzinga
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
Via Benzinga
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients
Via Benzinga
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
Via Benzinga
Why Shares of Phathom Pharmaceutical Jumped This Week
Via The Motley Fool
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
Via Benzinga
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
From Singapore Economic Development Board (EDB)A*STAR
Via ACN Newswire
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
Via Benzinga
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
Via Benzinga
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
Via Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
Via Benzinga
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
Via Benzinga
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
Via Benzinga
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
Via Benzinga
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
Via Benzinga
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
Via Benzinga
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.